Document Detail


Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
MedLine Citation:
PMID:  17178978     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The influence of left atrial size on cardiovascular events during antihypertensive treatment has not been reported previously from a long-term, prospective, randomized hypertension treatment trial. We recorded left atrial diameter by annual echocardiography and cardiovascular events in 881 hypertensive patients (41% women) with electrocardiographic left ventricular hypertrophy aged 55 to 80 (mean: 66) years during a mean of 4.8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Study. During follow-up, a total of 88 primary end points (combined cardiovascular death, myocardial infarction, or stroke) occurred. In Cox regression, baseline left atrial diameter/height predicted incidence of cardiovascular events (hazard ratio: 1.98 per cm/m [95% CI: 1.02 to 3.83 per cm/m]; P=0.042) adjusted for significant effects of Framingham risk score and history of atrial fibrillation. Greater left atrial diameter reduction during follow-up was associated with greater reduction in left ventricular hypertrophy, absence of new-onset atrial fibrillation or mitral regurgitation during follow-up, and losartan-based treatment (B=-0.13+/-0.03 cm/m; P<0.001) in multiple linear regression, adjusting for baseline left atrial diameter/height. However, in time-varying Cox regression analysis, left atrial diameter reduction was not independent of left ventricular hypertrophy regression in predicting cardiovascular events during follow-up. In conclusion, left atrial diameter/height predicts risk of cardiovascular events independent of other clinical risk factors in hypertensive patients with left ventricular hypertrophy and may be useful in pretreatment clinical assessment of cardiovascular risk in these patients.
Authors:
Eva Gerdts; Kristian Wachtell; Per Omvik; Jan Erik Otterstad; Lasse Oikarinen; Kurt Boman; Björn Dahlöf; Richard B Devereux
Related Documents :
15785148 - Rate control vs. rhythm control in the management of atrial fibrillation in elderly per...
22240768 - Percutaneous coronary intervention with or without on-site coronary artery bypass surge...
10666658 - Cost-effective strategies in the acute management of atrial fibrillation.
10979008 - Role of transthoracic echocardiography in atrial fibrillation.
2048568 - Circulatory abnormalities and compensatory mechanisms in heart failure.
17698228 - A close relationship between functional polymorphism in the promoter region of matrix m...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-12-18
Journal Detail:
Title:  Hypertension     Volume:  49     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-19     Completed Date:  2007-02-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  311-6     Citation Subset:  IM    
Affiliation:
Institute of Medicine, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway. gerdtsev@online.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antihypertensive Agents / therapeutic use*
Atenolol / therapeutic use
Cardiovascular Diseases / etiology*,  mortality
Echocardiography, Doppler*
Female
Follow-Up Studies
Heart Atria*
Humans
Hypertension / complications*,  drug therapy*,  ultrasonography
Hypertrophy, Left Ventricular / etiology,  ultrasonography
Incidence
Losartan / therapeutic use*
Male
Middle Aged
Predictive Value of Tests
Risk Assessment
Stroke / epidemiology,  etiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 114798-26-4/Losartan; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a prelimin...
Next Document:  Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.